Lotte Bio Unveils Next-Generation 'ADC Platform'... Songdo CDMO Plant to Begin Commercial Production in 2027

James Park Announces Global Expansion at JPMHC
Lotte Third-Generation Executive Shin Yooyeol Attends and Meets with Clients

Lotte Biologics unveiled 'SoluFlex Link,' a platform that supports the development and production of antibody-drug conjugate (ADC) therapeutics, a next-generation cancer treatment technology attracting attention. The CDMO plant in Songdo is set to begin commercial production in 2027.

James Park, CEO of Lotte Biologics, is presenting at the 'JP Morgan Healthcare Conference' held in San Francisco, USA, on the 16th (local time). Photo by Lotte Biologics

James Park, CEO of Lotte Biologics, participated as a presenter in the Asia-Pacific (APAC) track at the 'JP Morgan Healthcare Conference (JPMHC)' held in San Francisco, USA, on the 16th (local time), expressing his ambition to accelerate the leap into the global CDMO market.

ADC is a form of anticancer drug in which an antibody and a drug are chemically linked through a connecting substance called a linker, characterized by targeting and attacking only the intended cancer cells. SoluFlex Link is an ADC platform applying proprietary linker technology jointly developed by Lotte Biologics and 'Kanaf Therapeutics,' a bio venture based on drug conjugation technology.

CEO Park stated, "We believe this technology can be utilized by ADC new drug developers for various research and development by improving the instability, a major drawback of ADC therapeutics, and enabling its use with diverse antibodies and payloads." He added, "It can simultaneously increase production yield and therapeutic efficacy, making it an optimized solution for next-generation ADC development and production."

Park also presented a blueprint for the successful CDMO transition of the Syracuse Bio Campus in New York and the Songdo Bio Campus.

Following the acquisition of BMS's biopharmaceutical production facility in Syracuse, New York, USA, at the end of 2022, Lotte Biologics broke ground on the first plant of the Songdo Bio Campus in Incheon last March. The Songdo Plant 1 aims for full-scale commercial production starting in 2027. TheSyracuse Bio Campus received flawless quality-level evaluations during last year's inspections by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan and the regular audit by the U.S. Food and Drug Administration (FDA).

CEO Park emphasized, "Even after acquiring the plant, we have maintained a high-quality production system and demonstrated capabilities as a global CDMO company." The company also explained, "This was an opportunity to prove that we have production facilities meeting international standards and a global quality management system capable of producing high-quality biopharmaceuticals."

Park said, "The Songdo Bio Campus Plant 1, scheduled for completion this year, will be a flexible large-scale production facility equipped with an optimized operating system." He added, "By applying automated production processes and advanced manufacturing technologies, and maximizing operational efficiency by leveraging the geographical advantages of Songdo and New York, we will strive to become a global company with customer satisfaction and quality competitiveness."

Meanwhile, Shin Yoo-yeol, Vice President and Head of Global Strategy at Lotte Biologics, also attended the JPMHC for the first time. According to the company, Vice President Shin participated in presentation sessions by Roche, Johnson & Johnson (J&J), BMS, and others to observe the latest trends in the global pharmaceutical and bio industries, and joined business and partnership meetings with global pharmaceutical companies and potential clients alongside CEO Park.

This content was produced with the assistance of AI translation services.